Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manja Reimann

Showing results (41-50 of 43) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 43 results.
The American Journal of Clinical Nutrition|March 9, 2006
Soy-isoflavone-enriched foods and markers of lipid and glucose metabolism in postmenopausal women: interactions with genotype and equol productionWendy L Hall, Katerina Vafeiadou, Jesper Hallund, et al.
Journal of Hypertension|January 17, 2012
Facilitated defensive coping, silent ischaemia and ECG left-ventricular hypertrophy: the SABPA studyLeoné Malan, Mark Hamer, Markus P Schlaich, et al.
British Journal of Haematology|April 9, 2024
Gemtuzumab ozogamicin plus midostaurin in combination with standard '7 + 3' induction therapy in newly diagnosed AML: Results from the SAL-MODULE phase I studyChristoph Röllig, Christoph Schliemann, Leo Ruhnke, et al.
Pageof 5

Showing results (41-50 of 43) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 43 results.
The American Journal of Clinical Nutrition|March 9, 2006
Soy-isoflavone-enriched foods and markers of lipid and glucose metabolism in postmenopausal women: interactions with genotype and equol productionWendy L Hall, Katerina Vafeiadou, Jesper Hallund, et al.
Journal of Hypertension|January 17, 2012
Facilitated defensive coping, silent ischaemia and ECG left-ventricular hypertrophy: the SABPA studyLeoné Malan, Mark Hamer, Markus P Schlaich, et al.
British Journal of Haematology|April 9, 2024
Gemtuzumab ozogamicin plus midostaurin in combination with standard '7 + 3' induction therapy in newly diagnosed AML: Results from the SAL-MODULE phase I studyChristoph Röllig, Christoph Schliemann, Leo Ruhnke, et al.
Pageof 5